FTC Seeks to Block Sanofi's Acquisition of Rare Disease Drug that Threatens Sanofi's Monopoly - Federal Trade Commission News
ftc.govSubmitted by ftcgov2783 in business
The Federal Trade Commission is seeking to block Sanofi’s proposed acquisition of an exclusive license to Maze Therapeutics Inc.’s therapy in development for treatment of Pompe disease.